Fig. 4From: Avidity characterization of genetically engineered T-cells with novel and established approachespp65-TCR and TARP-TCR-engineered T-cells show therapeutic effect when encountering HLA-A2 positive target cells presenting the cognate peptide. Sorted and expanded pp65-TCR and TARP-TCR-engineered human T-cells were assayed for response in IFN-γ production (a, magnified in b) and killing (c) of HLA-A2+ mel526 target cells pulsed with a range of peptide concentrations. Inactivation of target cells was also assayed at various effector to target cell ratios with target cells pulsed with 10 μM peptide (d)Back to article page